DarioHealth

DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. The firm solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DarioHealth excels in Q4 2022 with B2B growth and strategic partnerships

DarioHealth's Q4 2022 marked strong financial performance and operational efficiency gains.
Strategic focus on B2B model and multi-condition management driving revenue growth.
Challenges include managing increased expenses and maintaining high gross margin targets.
Opportunities lie in expanding client base, strategic integrations, and revenue diversification.

DarioHealth reports revenue growth and strategic partnerships driving future expansion

DarioHealth's Q1 2023 performance showed revenue growth, improved margins, and strategic focus on B2B.
Strong partnerships with Amwell and Sanofi position the company for multi-condition agreements and revenue growth.
Operational challenges in DTC margins and user comparison require attention for sustained growth.
Opportunities lie in hospitalization reduction, revenue growth from partnerships, and market expansion through Aetna launch.

DarioHealth reports steady Q2 performance, eyes growth through partnerships

DarioHealth's Q2 2023 performance showcased steady B2B2C ARR growth despite flat revenue, with improving gross margins and reduced operating losses, supported by a strong cash position.
The company's strengths lie in strategic partnerships, market fit, and operational efficiency, while facing challenges in revenue growth rates and optimizing expenses.
Opportunities ahead include revenue growth through partnerships and new product launches, leveraging AI for engagement and cost efficiencies, and sustaining a software-driven business model.

DarioHealth reports growth in Q3 2023, eyes revenue diversification

DarioHealth's Q3 2023 showed growth and improved financial metrics.
Strategic partnerships and revenue diversification are key strengths.
Challenges include predicting revenue recognition and cost management.
Opportunities lie in revenue growth and becoming cash flow positive.

DarioHealth reports robust Q4 results, eyes growth through strategic acquisitions

DarioHealth's strong Q4 performance and strategic acquisitions position the company for growth in 2024 and 2025, with a focus on profitability and revenue expansion.
While facing challenges in revenue scaling and cost reduction, the company's strengths in cash position, innovation, and leadership integration provide a solid foundation for success.
Opportunities lie in revenue growth from partnerships and acquisitions, integration synergies, and advancements in digital solutions, driving DarioHealth's path to market differentiation and financial success.

DarioHealth excels in Q1 2024, eyes profitability post Twill merger

DarioHealth's strong Q1 performance driven by B2B2C growth, poised for profitability post Twill merger. Focus on product integration and revenue expansion in key channels.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DarioHealth Corp. is a digital health company which offers a user-centric and multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth serves customers globally. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

New accounts demonstrate continued demand for integrated and holistic digital chronic condition management solutions NEW YORK , Sept. 20, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today two new employer contracts, including one for the full suite of integrated solutions.

DarioHealth Announces Two New Employer Contracts

DarioHealth Corp (NASDAQ:DRIO ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Glenn Garmont - LifeSci Advisors Erez Raphael - CEO & Director Richard Anderson - President & GM, North America Conference Call Participants Charles Rhyee - Cowen and Company Alexander Nowak - Craig-Hallum Rahul Rakhit - LifeSci Capital David Grossman - Stifel, Nicolaus & Company Benjamin Haynor - Alliance Global Partners Nathan Weinstein - Aegis Capital Corporation John Vandermosten - Zacks Small-Cap Research Operator Greetings, and welcome to the DarioHealth Corp. Second Quarter 2020 Results Conference Call. [Operator Instructions].

DarioHealth Corp (DRIO) CEO Erez Raphael on Q2 2022 Results - Earnings Call Transcript

Q2 revenue of 6.2 million, a 17.5% increase from the $5.3 million of the second quarter of 2021. Six-month year-to-date revenue totaled $14.2 million, a  60.8% increase over the first six months of 2021 $55 million in total commercial contract value reflecting continued strong momentum across Business-to-Business-to-Consumer (B2B2C) channels Selected by a national health plan as strategic behavioral health partner, providing reach to nearly ten million additional members Sanofi and other strategic partnerships gaining traction and expected to accelerate recurring revenue streams from employers and health plans Improved financial profile as company completes shift to B2B2C focus and reports $68 million of cash and equivalents on the balance sheet as of June 30 Company to host conference call and webcast 8:30 am ET today NEW YORK , Aug. 15, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, today reported financial results for the second quarter 2022 and provided a corporate and commercial update.

DarioHealth Reports Second Quarter 2022 Financial and Operating Results

The research examines Dario's ability to improve the health of members in rural areas compared to their urban counterparts and found the solution to be equally effective NEW YORK , Aug. 12, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today new research presented at the Association of Diabetes Care and Education Specialists ("ADCES") Annual Conference being held August 11 th to August 15 th, 2022 in Baltimore, Maryland. Rural residents face distinct challenges when it comes to health.

DarioHealth Presents New Research Demonstrating the Ability to Support People in Rural Areas and Deliver Lasting Health Improvements

Dario's digital behavioral health solution will help to improve access and navigation across mental health resources NEW YORK , Aug. 11, 2022 /PRNewswire/ -- DarioHealth Corp. ("Dario", "DarioHealth" or the "Company") (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that a national health plan (the "Plan"), selected Dario's behavioral health solution to drive self-service across its mental wellbeing care resources. Dario's solution will become part of the Plan's behavioral health platform to increase access to digital navigation, digital self-help and coaching.

DarioHealth Selected by National Health Plan to Enhance Mental Health and Well-Being for Members

Company to host conference call and webcast at 8:30 am ET NEW YORK , Aug. 10, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, today announced it would release its financial results for the second quarter ended June 30, 2022, on Monday, August 15, 2022. The company will host a conference call and webcast at 8:30 am Eastern Time.

DarioHealth to Report Second Quarter 2022 Results on Monday, August 15

The studies underscore the value of Dario's integrated behavioral health solution to help more people connect to effective care that is right for their needs NEW YORK , Aug. 4, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today new research presented at the American Psychological Association ("APA") Annual Convention being held August 4 th to 6th, 2022 in Minneapolis, Minnesota and virtually. People living with chronic conditions are 2 to 3 times more likely to experience depression or anxiety than those living without a chronic illness, and untreated depression or anxiety often leads to poor health outcomes.

DarioHealth Presents New Research Demonstrating the Impact of a Digital Solution on Depression and Anxiety at the American Psychological Association Annual Convention

Demand for Dario's single approach to chronic condition management continues to show strong demand NEW YORK , July 21, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced a new contract to deliver its full suite of integrated chronic condition management solutions to a national employer.  The new account is expected to launch in the third quarter of 2022.

DarioHealth Demonstrates Continued Growth in Multi-Chronic Contracts with Latest Addition of a National Employer for the Full Solution Suite

Dario continues to grow footprint in the employer market NEW YORK , June 21, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced a new contract to deliver its digital behavioral health solution for a leading provider of integrated technology solutions for financial professionals. The new account is expected to launch in the third quarter of 2022.

DarioHealth Announces New Contract with a National Employer

The addition of Dario's hypertension solution expands Solera's suite of best-in-class digital and community evidence-based health solutions PHOENIX , June 15, 2022 /PRNewswire/ -- Solera Health, the premier platform for connecting people seamlessly and easily to proven, personalized health solutions, announces its partnership with DarioHealth, a leading digital therapeutics company revolutionizing how people with chronic conditions manage their health through a user-centric platform. Together, Solera and DarioHealth are offering a turnkey, world class solution for treating hypertension, requiring just one contract and one technical integration to make this compelling new solution quickly available for payers' and employers' member populations.

Solera Health Adds DarioHealth to Its Cardiometabolic Network to Offer Hypertension Management Solutions

Dario Health (DRIO) Poised to Inflect Upon Full Launch of National Health Plan - Fundamentals: Company positioned to avoid dilutive financing after recent $50M credit facility with OrbiMed - Catalysts: Company is guiding for a full launch of a large national insurer, by end of June -.

Dario Health (DRIO) Poised To Inflect Upon Full Launch of National Health Plan

Investment from Elite Healthcare Fund Provides Validation, Access to Capital and Significant Runway to Execute on Strategic Operating Plan NEW YORK , June 9, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today it closed a senior secured term loan facility of up to $50 million with OrbiMed, a leading investor in the healthcare industry, providing non-dilutive capital to fund the continued development of its platform and the acceleration of its adoption in the multi-billion dollar global chronic disease management market.     The five-year, $50 million facility is structured with a $25 million loan at closing and an additional $25 million available for a future draw before June 30, 2023, subject to Dario achieving certain revenue thresholds.

DarioHealth Secures $50 Million Dollar Non-Dilutive Credit Facility with OrbiMed

The studies demonstrated significant improvement in glucose control and reductions in blood pressure for users managing diabetes and hypertension and improvement in clinical measures for users with diabetes, stress and depression. The third study demonstrates that the Dario solution has similar positive impact on diabetes across ethnicities.

DarioHealth Presents Three New Studies Demonstrating Improved Health in Users with Multiple Conditions at the American Diabetes Association's 82nd Scientific Sessions

Two new B2B contracts reinforce Dario's position as an emerging leader in multi-chronic digital health NEW YORK , May 19, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today two new contracts to provide digital therapeutics solutions to a national employer and a provider, both of which are expected to begin enrolling members in the third quarter of 2022.   The Texas-based, national employer selected Dario to provide digital behavioral health support for employees in 17 states across the south and southeast United States; the east-coast provider group chose Dario to provide its integrated metabolic solution for patients living with diabetes, high blood pressure and weight management support.

DarioHealth Announces Additional Commercial Contracts for its Digital Therapeutic Solutions

DarioHealth Corp. (NASDAQ:DRIO ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Glenn Garmont - Investor Relations Erez Raphael - Chief Executive Officer Rick Anderson - President & General Manager, North America Conference Call Participants Charles Rhyee - Cowen Rahul Rakhit - LifeSci Capital Nathan Weinstein - Aegis Capital John Vandermosten - Zacks David Grossman - Stifel Operator Good morning and welcome to the DarioHealth First Quarter 2022 Results Call. all participants will be in listen-only mode.

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q1 2022 Results - Earnings Call Transcript

Total Q1 revenue of $8.06 million increased 124% over the comparable prior year period and 34% sequentially over Q4 2021 Accelerated Business-to-Business (B2B) transformation with 14 new B2B accounts in Q1 2022, including two health plans Expanded GAAP gross margin to 49.4% and non-GAAP gross margin to 61% Improved overall financial profile with increasing B2B revenue and reduced operating costs as B2B business matures resulting in a lower net loss compared to Q4 2021 Company to host conference call and webcast 8:30 am ET today NEW YORK , May 12, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today reported financial results for the first quarter 2022 and provided a corporate and commercial update. "Our first quarter results reflect our increasingly successful transition to a B2B model with growing revenue and gross margins," stated Erez Raphael, Chief Executive Officer of Dario.

DarioHealth Reports Record Quarterly Revenues in its 2022 First Quarter

Teladoc (NYSE: TDOC) stock recently cratered to a new 52 week low following it's Q1 report. Some of it's shortfall was attributed by management to longer sales cycles in the insurer and employer space in addition to competitive concerns.

Is Dario (DRIO) Health Eating Teladoc's (TDOC) Lunch? Q1 Earnings on Tap Thursday After Meeting with Sanofi (SNY)

Company to host conference call and webcast at 8:30 am ET NEW YORK , May 4, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced it would release its financial results for the first quarter ended March 31, 2022 on Thursday, May 12, 2022. The company will host a conference call and webcast at 8:30 am Eastern Time.

DarioHealth to Report First Quarter 2022 Results on Thursday, May 12

New research offers fresh evidence that a single digital therapeutics platform can improve outcomes for commonly co-occurring conditions NEW YORK , April 27, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced the publication of a retrospective, real-world study demonstrating the impact of managing diabetes and weight together on a single digital platform at the Advanced Technologies and Treatments for Diabetes (ATTD) Conference being held April 27 th – 30th in Barcelona and online. To better understand the impact of an integrated, multi-condition digital therapeutics platform, Dario analyzed 12 months of real-world retrospective data for a group of 715 individuals using the Dario app to manage their blood sugar and demonstrating a Body Mass Index (BMI) of greater than 30 kg/m2, the clinical baseline for obesity.

DarioHealth Presents New Clinical Research Demonstrating Improved Outcomes for Participants Using a Single Integrated Digital Solution to Manage Multiple Chronic Conditions

New health plan partnership improves access to digital health for historically underserved populations NEW YORK, April 14, 2022  /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today a new agreement with Colorado Access, the largest public sector health plan in the state of Colorado, to provide digital chronic condition management solutions for its Medicaid population beginning with thousands of its members in the second quarter of 2022.     Colorado Access selected Dario to help improve the health of members living with diabetes and hypertension, as well as members with weight management and behavioral health needs through Dario's person-centric and integrated chronic condition platform.

DarioHealth Announces Agreement with Health Plan Colorado Access

NEW YORK, March 23, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today two new employer agreements: first, with a U.S. based social platform employer and second, with a global health care company. The contracts are expected to launch in the second quarter of 2022.

DarioHealth Announces Additional New Employer Contracts

DarioHealth's (DRIO) CEO Erez Raphael on Q4 2021 Results - Earnings Call Transcript

NEW YORK, March 22, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today reported financial results for the fourth quarter and full year 2021 and provided a corporate and commercial update. "The last year completely transformed Dario's company profile as our business-to-business (B2B) business grew significantly, both in terms of signed and launched, revenue-generating accounts and the overall growth of opportunity attributed to our integrated, multi-condition approach.

DarioHealth Reports Fourth Quarter and Full Year 2021 Results and Operational Highlights

NEW YORK, March 14, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced it would release its financial results for the fourth quarter and full year ended December 31, 2021 on Monday, March 21, 2022, after the close of trading. The company will host a conference call and webcast on Tuesday, March 22, at 8:30 am Eastern Time.

DarioHealth to Report Fourth Quarter and Full Year 2021 Results on Monday, March 21

NEW YORK , March 9, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today new agreements with a regional employer and a regional provider. The contracts are expected to launch in the second quarter of 2022.

News for DarioHealth Stock (DRIO)